Switch theme
Sign up to access all valuation multiples
Tchaikapharma Highquality Medicines AD is engaged in the business of manufacturing and selling pharmaceuticals in Bulgaria. The company specializes in both generic and in-licensed manufacturing. The company has medicines for Anaesthetics, Nervous system, Oncology, Anti-Inflammatory and Anti-Rheumatic, Antibiotics, Digestive system, diabetes and metabolism, and Respiratory system. The company generates all of its revenue from the sale of medicines. Geographically, the company generates the majority of its revenue from Bulgaria.
2000
207
Last FY Revenue $30.9M
Last FY EBITDA $4.7M
$932M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, TchaikaPharma achieved revenue of $30.9M and an EBITDA of $4.7M.
TchaikaPharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TchaikaPharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $30.9M | XXX | XXX | XXX |
| Gross Profit | XXX | $10.3M | XXX | XXX | XXX |
| Gross Margin | XXX | 33% | XXX | XXX | XXX |
| EBITDA | XXX | $4.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 15% | XXX | XXX | XXX |
| EBIT | XXX | $3.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | 11% | XXX | XXX | XXX |
| Net Profit | XXX | $2.6M | XXX | XXX | XXX |
| Net Margin | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | $5.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, TchaikaPharma's stock price is BGN 17 (or $10).
TchaikaPharma has current market cap of BGN 1.6B (or $925M), and EV of BGN 1.6B (or $932M).
See TchaikaPharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $932M | $925M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, TchaikaPharma has market cap of $925M and EV of $932M.
TchaikaPharma's trades at 30.1x EV/Revenue multiple, and 197.7x EV/EBITDA.
Equity research analysts estimate TchaikaPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TchaikaPharma's P/E ratio is not available.
See valuation multiples for TchaikaPharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $925M | XXX | $925M | XXX | XXX | XXX |
| EV (current) | $932M | XXX | $932M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 30.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 197.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 277.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 355.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 478.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTchaikaPharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $33K for the same period.
TchaikaPharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TchaikaPharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for TchaikaPharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $33K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TchaikaPharma acquired XXX companies to date.
Last acquisition by TchaikaPharma was XXXXXXXX, XXXXX XXXXX XXXXXX . TchaikaPharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was TchaikaPharma founded? | TchaikaPharma was founded in 2000. |
| Where is TchaikaPharma headquartered? | TchaikaPharma is headquartered in Bulgaria. |
| How many employees does TchaikaPharma have? | As of today, TchaikaPharma has 207 employees. |
| Is TchaikaPharma publicy listed? | Yes, TchaikaPharma is a public company listed on BUL. |
| What is the stock symbol of TchaikaPharma? | TchaikaPharma trades under THQM ticker. |
| When did TchaikaPharma go public? | TchaikaPharma went public in 2012. |
| Who are competitors of TchaikaPharma? | Similar companies to TchaikaPharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of TchaikaPharma? | TchaikaPharma's current market cap is $925M |
| Is TchaikaPharma profitable? | Yes, TchaikaPharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
